Novocure计划基于PANOVA-3，提交肿瘤电场治疗用于治疗不可切除、局部晚期胰腺癌的注册批准，并计划提交PANOVA-3的数据在即将举行的医学大会上进行公布。再鼎医药计划在中国提交注册申请。Zai Lab (09688) rose by over 4%, as of the time of this report, it is up by 4.67%, trading at 23.55 Hong Kong dollars, with a turnover of 16.0669 million Hong Kong dollars.
According to the International Finance News app, Zai Lab (09688) rose by over 4%, as of the time of this report, it is up by 4.67%, trading at 23.55 Hong Kong dollars, with a turnover of 16.0669 million Hong Kong dollars.
On the news front, Zai Lab and Novocure announced that the pivotal Phase 3 PANOVA-3 study of tumor-treating fields achieved its primary endpoint, demonstrating statistically significant improvement in median overall survival (mOS) compared to the control group. PANOVA-3 evaluated tumor-treating fields combined with gemcitabine and nab-paclitaxel for first-line treatment of unresectable locally advanced pancreatic cancer.
Novocure plans to seek regulatory approval for the use of tumor-treating fields in the treatment of unresectable locally advanced pancreatic cancer based on PANOVA-3, and intends to present the data from PANOVA-3 at an upcoming medical conference. Zai Lab plans to submit a registration application in China.
